Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Awss Shalhoub

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cureus|June 17, 2024
Spontaneous Hemopericardium Associated With Apixaban Use With Newly Diagnosed Malignancy and Acute Kidney Injury: A Case ReportAwss Shalhoub, Omar M Masarweh, Nicole Brenner
International Journal of Dermatology|April 11, 2019
Cutaneous leishmaniasis: an evolving disease with ancient rootsMaelle Saliba, Awss Shalhoub, Suad Taraif, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|August 22, 2024
Clopidogrel-Mediated P2Y<sub>12</sub> Inhibition According to Renal Function in Patients With Diabetes Mellitus and CADLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
JACC. Cardiovascular Interventions|April 10, 2024
P2Y<sub>12</sub> Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 StudyLuis Ortega-Paz, Wilbert Bor, Francesco Franchi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cureus|June 17, 2024
Spontaneous Hemopericardium Associated With Apixaban Use With Newly Diagnosed Malignancy and Acute Kidney Injury: A Case ReportAwss Shalhoub, Omar M Masarweh, Nicole Brenner
International Journal of Dermatology|April 11, 2019
Cutaneous leishmaniasis: an evolving disease with ancient rootsMaelle Saliba, Awss Shalhoub, Suad Taraif, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|August 22, 2024
Clopidogrel-Mediated P2Y<sub>12</sub> Inhibition According to Renal Function in Patients With Diabetes Mellitus and CADLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
JACC. Cardiovascular Interventions|April 10, 2024
P2Y<sub>12</sub> Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 StudyLuis Ortega-Paz, Wilbert Bor, Francesco Franchi, et al.
Pageof 1